PrescriberPub Date : 2024-03-01DOI: 10.1002/psb.2117
Joy Ogden
{"title":"Focusing on what matters to the patient when prescribing","authors":"Joy Ogden","doi":"10.1002/psb.2117","DOIUrl":"https://doi.org/10.1002/psb.2117","url":null,"abstract":"As Head of Effective Prescribing and Therapeutics for the Scottish Government, Dr Alpana Mair is responsible for advising ministers on the safe, sustainable and effective use of medicines. Here, she talks to Joy Ogden about her work tackling polypharmacy and ensuring the focus is on what matters to the patient when prescribing.","PeriodicalId":20432,"journal":{"name":"Prescriber","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140273481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PrescriberPub Date : 2024-03-01DOI: 10.1002/psb.2120
Steve Chaplin
{"title":"Atogepant for the prophylaxis of migraine in adults","authors":"Steve Chaplin","doi":"10.1002/psb.2120","DOIUrl":"https://doi.org/10.1002/psb.2120","url":null,"abstract":"Atogepant (Aquipta) is a new oral CGRP‐receptor antagonist indicated for the prophylaxis of migraine in adults. This article discusses its indication, efficacy and adverse effects.","PeriodicalId":20432,"journal":{"name":"Prescriber","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140268420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PrescriberPub Date : 2024-03-01DOI: 10.1002/psb.2118
Chitra V Nair
{"title":"Prevention, diagnosis and treatment of actinic keratosis","authors":"Chitra V Nair","doi":"10.1002/psb.2118","DOIUrl":"https://doi.org/10.1002/psb.2118","url":null,"abstract":"Actinic keratoses are common in the UK, especially in lighter skinned individuals and those with high lifetime UV exposure. As they are considered premalignant and can progress to squamous cell carcinoma, early identification and treatment are important. This article provides a guide to the prevention, recognition and management of actinic keratosis.","PeriodicalId":20432,"journal":{"name":"Prescriber","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140277956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PrescriberPub Date : 2024-03-01DOI: 10.1002/psb.2114
{"title":"Something for everyone as spring arrives","authors":"","doi":"10.1002/psb.2114","DOIUrl":"https://doi.org/10.1002/psb.2114","url":null,"abstract":"","PeriodicalId":20432,"journal":{"name":"Prescriber","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140280599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PrescriberPub Date : 2024-01-01DOI: 10.1002/psb.2111
Steve Titmarsh
{"title":"Society for Academic Primary Care Annual Scientific Meeting","authors":"Steve Titmarsh","doi":"10.1002/psb.2111","DOIUrl":"https://doi.org/10.1002/psb.2111","url":null,"abstract":"What do GP specialists add to epilepsy care? How can polypharmacy be optimised? And how do clinicians feel about stopping antidepressants? These were just a small sample of questions that research presented at the 51st Annual Scientific Meeting of the Society for Academic Primary Care, held in Brighton in July 2023, tried to address.","PeriodicalId":20432,"journal":{"name":"Prescriber","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139638299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PrescriberPub Date : 2024-01-01DOI: 10.1002/psb.2108
Emmanuel Okenyi, Lauren Walker
{"title":"Advantages and challenges of AI in enhancing healthcare equity","authors":"Emmanuel Okenyi, Lauren Walker","doi":"10.1002/psb.2108","DOIUrl":"https://doi.org/10.1002/psb.2108","url":null,"abstract":"The potential benefits of artificial intelligence (AI) in healthcare are wide ranging, from drug discovery to clinical decision making to improving health equity. This article focuses on the advantages and potential pitfalls of using AI to enhance equity and fairness in healthcare.","PeriodicalId":20432,"journal":{"name":"Prescriber","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139634140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PrescriberPub Date : 2024-01-01DOI: 10.1002/psb.2107
{"title":"2024 heralds a year of change for Prescriber","authors":"","doi":"10.1002/psb.2107","DOIUrl":"https://doi.org/10.1002/psb.2107","url":null,"abstract":"","PeriodicalId":20432,"journal":{"name":"Prescriber","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139537921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PrescriberPub Date : 2024-01-01DOI: 10.1002/psb.2110
M. Greener
{"title":"Statins: 30 years after the landmark 4S study","authors":"M. Greener","doi":"10.1002/psb.2110","DOIUrl":"https://doi.org/10.1002/psb.2110","url":null,"abstract":"The initial excitement inspired by the landmark clinical trials demonstrating the benefits of statins for the prevention of cardiovascular disease was soon dampened by reports of adverse events. Tolerability has remained a controversial topic ever since. However, recent studies suggest that most reported adverse effects of statins can be attributed to the nocebo effect.","PeriodicalId":20432,"journal":{"name":"Prescriber","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139637017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
PrescriberPub Date : 2024-01-01DOI: 10.1002/psb.2113
Steve Chaplin
{"title":"Mavacamten for obstructive hypertrophic cardiomyopathy","authors":"Steve Chaplin","doi":"10.1002/psb.2113","DOIUrl":"https://doi.org/10.1002/psb.2113","url":null,"abstract":"Mavacamten (Camzyos) is a cardiac myosin inhibitor indicated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy. This article discusses its efficacy, adverse effects and place in therapy.","PeriodicalId":20432,"journal":{"name":"Prescriber","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139636618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
求助内容：
应助结果提醒方式：